Advances in the nutritional and pharmacological management of phenylketonuria

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 17, Issue 1, 2014, Pages 61-68

  Ney, Denise M ^a   Blank, Robert D ^b   Hansen, Karen E ^c  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b Department of Medicine   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Bone biomechanical performance; Glycomacropeptide; Large neutral amino acids; Phenylketonuria; Tetrahydrobiopterin

Indexed keywords

AMINO ACID; CHAPERONE; GLYCOPROTEIN; GUANOSINE PHOSPHATE; PHENYLALANINE; TETRAHYDROBIOPTERIN;

AMINO ACID TRANSPORT; BONE FRAGILITY; BONE STRENGTH; CLINICAL EFFECTIVENESS; DIET SUPPLEMENTATION; DIET THERAPY; HUMAN; NUTRITION; PHENYLKETONURIA; REVIEW;

MURINAE;

AMINO ACIDS; BIOPTERIN; BONE AND BONES; CASEINS; DIETARY SUPPLEMENTS; HUMANS; MILK PROTEINS; MUTATION; PEPTIDE FRAGMENTS; PHENYLALANINE; PHENYLALANINE HYDROXYLASE; PHENYLKETONURIAS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TYROSINE;

EID: 84891042377     PISSN: 13631950     EISSN: 14736519     Source Type: Journal    
DOI: 10.1097/MCO.0000000000000002     Document Type: Review

References (41)

1. Berry SA, Brown C, Grant M, et al. Newborn screening 50 years later: access issues faced by adults with PKU. Genet Med 2013; 15: 591-599. This review summarizes the prevalence of PKU and individual patient, social and economic factors preventing more than 70% of adults PKU patients in the United States from accessing treatment.
2. Flydal MI, Martinez A. Phenylalanine hydroxylase: function, structure, and regulation. IUBMB Life 2013; 65: 341-349.
3. Lindegren M, Krishnaswami S, Fonnesbeck C, et al. Adjuvant treatment for phenylketonuria (PKU). Comparative effectiveness review No. 56. Rockville, MD: Agency for Healthcare Research and Quality; Feb 2012; AHRQ Publication No 12-EHC035-EF. Systematic review of evidence on adjuvant treatment of PKU, including sapropterin dihydrochloride (BH4) and large neutral amino acid supplementation, conducted by the Vanderbilt Evidence-Based Practice Center under contract to the Agency for Healthcare Research and Quality and presented at the NIH Scientific Review of Evidence for PKU conference held February 2012.
4. Vockley J, Andersson HC, Antshel KM, et al. ACMG guideline for phenylalanine hydroxylase (PAH) deficiency: diagnosis and management. Genet Med 2014; In press. Recommendations for the treatment of PKU based in part on a comparative effectiveness reviewconducted by the Vanderbilt Evidence-Based Practice Center under contract to the Agency for Healthcare Research and Quality and presented at the NIH Scientific Review of Evidence for PKU conference held February 2012.
5. Camp KM, Lloyd-Puryear MA, Huntington KL. Nutritional treatment for inborn errors of metabolism: indications, regulations, and availability of medical foods and dietary supplements using phenylketonuria as an example. Mol Genet Metab 2012; 107: 3-9.
6. Hartnett C, Salvarinova-Zivkovic R, Yap-Todos E, et al. Long-term outcomes of blood phenylalanine concentrations in children with classical phenylketonuria. Mol Genet Metab 2013; 108: 255-258.
7. Van Calcar SC, Ney DM. Food products made with glycomacropeptide, a lowphenylalanine whey protein, provide a new alternative to amino acid-based medical foods for nutrition management of phenylketonuria. J Acad Nutr Diet 2012; 112: 1201-1210. Review of evidence and future research needs for utilization of GMP medical foods in the PKU diet.
8. Antenor-Dorsey JA, Hershey T, Rutlin J, et al. White matter integrity and executive abilities in individuals with phenylketonuria. Mol Genet Metab 2013; 109: 125-131.
9. de Groot MJ, Hoeksma M, van Rijn M, et al. Relationships between lumbar bone mineral density and biochemical parameters in phenylketonuria patients. Mol Genet Metab 2012; 105: 566-570.
10. Hennermann JB, Roloff S, Gellermann J, et al. Chronic kidney disease in adolescent and adult patients with phenylketonuria. J Inherit Metab Dis 2013; 36: 747-756.
11. Brody EP. Biological activities of bovine glycomacropeptide. Br J Nutr 2000; 84 (Suppl 1):S39-S46. (Pubitemid 32106828)
12. Ney DM, Gleason ST, van Calcar SC, et al. Nutritional management of PKU with glycomacropeptide from cheese whey. J Inherit Metab Dis 2009; 32: 32-39.
13. Van Calcar SC, Macleod EL, Gleason ST, et al. Improved nutritional management of phenylketonuria by using a diet containing glycomacropeptide compared with amino acids. Am J Clin Nutr 2009; 89: 1068-1077.
14. Solverson P, Murali SG, Brinkman AS, et al. Glycomacropeptide, a lowphenylalanine protein isolated from cheese whey, supports growth and attenuates metabolic stress in the murine model of phenylketonuria. Am J Physiol Endocrinol Metab 2012; 302:E885-E895.
15. Xu SP, Mao XY, Cheng X, Chen B. Ameliorating effects of casein glycomacropeptide on obesity induced by high-fat diet in male Sprague-Dawley rats. Food Chem Toxicol 2013; 56: 1-7.
16. Burrage LC, McConnell J, Haesler R, et al. High prevalence of overweight and obesity in females with phenylketonuria. Mol Genet Metab 2012; 107: 43-48.
17. Dangin M, Boirie Y, Garcia-Rodenas C, et al. The digestion rate of protein is an independent regulating factor of postprandial protein retention. Am J Physiol Endocrinol Metab 2001; 280:E340-E348.
18. Macleod EL, Clayton MK, van Calcar SC, Ney DM. Breakfast with glycomacropeptide compared with amino acids suppresses plasma ghrelin levels in individuals with phenylketonuria. Mol Genet Metab 2011; 100: 303-308.
19. Greeves LG, Carson DJ, Magee A, Patterson CC. Fractures and phenylketonuria. Acta Paediatr 1997; 86: 242-244. (Pubitemid 27135268)
20. Modan-Moses D, Vered I, Schwartz G, et al. Peak bone mass in patients with phenylketonuria. J Inherit Metab Dis 2007; 30: 202-208. (Pubitemid 46488002)
21. McMurry MP, Chan GM, Leonard CO, Ernst SL. Bone mineral status in children with phenylketonuria: relationship to nutritional intake and phenylalanine control. Am J Clin Nutr 1992; 55: 997-1004.
22. Miras A, Boveda MD, Leis MR, et al. Risk factors for developing mineral bone disease in phenylketonuric patients. Mol Genet Metab 2013; 108: 149-154.
23. Solverson P, Murali SG, Litscher SJ, et al. Low bone strength is a manifestation of phenylketonuria in mice and is attenuated by a glycomacropeptide diet. PloS One 2012; 7:e45165. This study characterizes the PKU bone phenotype and the contributions of genotype and dietary protein source to the bone phenotype in Pahenu2 mice.
24. Frost HM. From Wolff's law to the Utah paradigm: insights about bone physiology and its clinical applications. Anat Rec 2001; 262: 398-419. (Pubitemid 32250965)
25. McBride SH, Silva MJ. Adaptive and injury response of bone to mechanical loading. Bonekey Osteovision 2012; 1:192.
26. Saito M, Marumo K. Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus. Osteoporos Int 2010; 21: 195-214.
27. Duque G, Li W, Vidal C, et al. Pharmacological inhibition of PPARgamma increases osteoblastogenesis and bone mass in male C57BL/6 mice. J Bone Miner Res 2013; 28: 639-648.
28. Manz F, Schmidt H, Scharer K, Bickel H. Acid-base status in dietary treatment of phenylketonuria. Pediatr Res 1977; 11 (10 Pt 2): 1084-1087. (Pubitemid 8228139)
29. Adeva MM, Souto G. Diet-induced metabolic acidosis. Clin Nutr 2011; 30: 416-421.
30. Bushinsky DA. Net calcium efflux from live bone during chronic metabolic, but not respiratory, acidosis. Am J Physiol 1989; 2565Pt2:F836-F842.
31. Jehle S, Hulter HN, Krapf R. Effect of potassium citrate on bone density, microarchitecture, and fracture risk in healthy older adults without osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 2013; 98: 207-217.
32. Ney DM. Does the PKU diet contribute to impaired renal function? J Inherit Metab Dis 2013; 36: 903-904.
33. van Spronsen FJ, de Groot MJ, Hoeksma M, et al. Large neutral amino acids in the treatment of PKU: from theory to practice. J Inherit Metab Dis 2010; 33: 671-676.
34. Vogel KR, Arning E, Wasek BL, et al. Nonphysiological amino acid (NPAA) therapy targeting brain phenylalanine reduction: pilot studies in PAH (ENU2) mice. J Inherit Metab Dis 2013; 36: 513-523. Studies in Pahenu2 mice provide proof-of-principle for the use of nonphysiological amino acids to act as competitive inhibitors of brain amino acid transporters.
35. Yano S, Moseley K, Azen C. Large neutral amino acid supplementation increases melatonin synthesis in phenylketonuria: a new biomarker. J Pediatr 2012; 162: 999-1003. This study demonstrates that levels of melatonin in blood and urine are an accessible biomarker reflecting brain serotonin synthesis in patients with PKU.
36. Walterfang M, Bonnot O, Mocellin R, Velakoulis D. The neuropsychiatry of inborn errors of metabolism. J Inherit Metab Dis 2013; 36: 687-702.
37. Dotremont H, Francois B, Diels M, Gillis P. Nutritional value of essential amino acids in the treatment of adults with phenylketonuria. J Inherit Metab Dis 1995; 18: 127-130.
38. Schindeler S, Ghosh-Jerath S, Thompson S, et al. The effects of large neutral amino acid supplements in PKU: an MRS and neuropsychological study. Mol Genet Metab 2007; 91: 48-54. (Pubitemid 46550929)
39. Heintz C, Cotton RG, Blau N. Tetrahydrobiopterin, its mode of action on phenylalanine hydroxylase, and importance of genotypes for pharmacological therapy of phenylketonuria. Hum Mutat 2013. [Epub ahead of print]. Detailed review of the phenylalanine hydroxylase system and the genetic, molecular, and metabolic basis for response to tetrahydrobiopterin therapy in PKU.
40. Keil S, Anjema K, van Spronsen FJ, et al. Long-term follow-up and outcome of phenylketonuria patients on sapropterin: a retrospective study. Pediatrics 2013; 131:e1881-e1888.
41. Staudigl M, Gersting SW, Danecka MK, et al. The interplay between genotype, metabolic state and cofactor treatment governs phenylalanine hydroxylase function and drug response. Hum Mol Genet 2011; 20: 2628-2641.